384 Outcome at 18 Months of Age After Sildenafil Therapy for Refractory Neonatal Hypoxemia

Autor: P Valencia, A Sola, H Baquero, Maria Elena Venegas, Freddy Neira, A Soliz
Rok vydání: 2005
Předmět:
Zdroj: Pediatric Research. 58:420-420
ISSN: 1530-0447
0031-3998
Popis: Background: There is still no sufficient evidence for the use of oral sildenafil for severe Pulmonary Hypertension of the Newborn, where there is no Nitric Oxide, High frequency Ventilation and/or ECMO. Despite only one proof of concept trial a few anecdotal reports and no report on safety, it is being offered in several regions as compassionate use. We performed detailed follow at 18 months of age to asses for adverse effects in the newborns who were treated with oral sildenafil in a randomized trial Objective: To analyze the outcome of term newborns who were treated with oral sildenafil for neonatal PPH in a region where iNO is unavailable. Design/Methods: Of the seven term newborns that were treated with oral Sildenafil during the study, five were alive at one year of age and four were followed up to 18 months. Anthropomorphic measurements, neurodevelopment assessment (Gesell developmental scale), magnetic resonance imaging (MRI), electroencephalogram (EEG), and otoacustic emissions (OAE) were done in all children. Results: The mean of height (77.5 cm.) weight (11.02 Kg.), head circumference (46.5 cm) and neurodevelopment evaluation on Gesell scales (102.7) were within normal limits. The neuro-imaging (MRI) and neurophysiologic studies (EEG and OAE) also were normal. Conclusions: From these results we cannot definitely conclude that oral sildenafil does not have a negative side effect. However, it is encouraging that this small group of infants did not have neurological sequelae that would prevent them from normal neurodevelopment, despite exposure to severe hipoxemia for periods greater than 12 hours.
Databáze: OpenAIRE